Literature DB >> 34099111

Neuroimmunology of depression.

Erika Sarno1, Adam J Moeser2, Alfred J Robison3.   

Abstract

Depression is one of the leading causes of disability worldwide and a major contributor to the global burden of disease, yet the cellular and molecular etiology of depression remain largely unknown. Major Depressive Disorder (MDD) is associated with a variety of chronic physical inflammatory and autoimmune disorders, and mood disorders may act synergistically with other medical disorders to worsen patient outcomes. Here, we outline the neuroimmune complement, explore the evidence for altered immune system function in MDD, and present some of the potential mechanisms by which immune cells and molecules may drive the onset and course of MDD. These include pro-inflammatory signaling, alterations in the hypothalamic-pituitary-adrenal axis, dysregulation of the serotonergic and noradrenergic neurotransmitter systems, neuroinflammation, and meningeal immune dysfunction. Finally, we discuss the interactions between current antidepressants and the immune system and propose the possibility of immunomodulatory drugs as potential novel antidepressant treatments.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressants; Brain; Depression; HPA axis; Meninges; Neuroimmunology

Mesh:

Substances:

Year:  2021        PMID: 34099111      PMCID: PMC8877598          DOI: 10.1016/bs.apha.2021.03.004

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  187 in total

Review 1.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Authors:  Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos
Journal:  Lancet       Date:  2013-08-29       Impact factor: 79.321

2.  Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE.

Authors:  Alison L Christy; Margaret E Walker; Martin J Hessner; Melissa A Brown
Journal:  J Autoimmun       Date:  2012-12-23       Impact factor: 7.094

3.  Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys.

Authors:  Esme Fuller-Thomson; Joanne Sulman
Journal:  Inflamm Bowel Dis       Date:  2006-08       Impact factor: 5.325

4.  Sex differences in hippocampal long-term potentiation (LTP) and Pavlovian fear conditioning in rats: positive correlation between LTP and contextual learning.

Authors:  S Maren; B De Oca; M S Fanselow
Journal:  Brain Res       Date:  1994-10-24       Impact factor: 3.252

5.  Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide.

Authors:  Amel Messaoud; Rym Mensi; Wahiba Douki; Fadoua Neffati; Mohamed Fadhel Najjar; Gabriella Gobbi; Flavia Valtorta; Lotfi Gaha; Stefano Comai
Journal:  World J Biol Psychiatry       Date:  2018-05-23       Impact factor: 4.132

6.  Ketamine induces apoptosis via the mitochondrial pathway in human lymphocytes and neuronal cells.

Authors:  S Braun; N Gaza; R Werdehausen; H Hermanns; I Bauer; M E Durieux; M W Hollmann; M F Stevens
Journal:  Br J Anaesth       Date:  2010-07-21       Impact factor: 9.166

Review 7.  A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence.

Authors:  P Blier; C de Montigny; Y Chaput
Journal:  J Clin Psychiatry       Date:  1990-04       Impact factor: 4.384

8.  Country- and individual-level socioeconomic determinants of depression: multilevel cross-national comparison.

Authors:  Dheeraj Rai; Pedro Zitko; Kelvyn Jones; John Lynch; Ricardo Araya
Journal:  Br J Psychiatry       Date:  2013-01-24       Impact factor: 9.319

9.  Racial-ethnic disparities in use of antidepressants in private coverage: implications for the Affordable Care Act.

Authors:  Kyoungrae Jung; Dooyoung Lim; Yunfeng Shi
Journal:  Psychiatr Serv       Date:  2014-09-01       Impact factor: 3.084

10.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

Authors:  Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

View more
  2 in total

Review 1.  Will Sirtuin 2 Be a Promising Target for Neuroinflammatory Disorders?

Authors:  Zhang Fan; Li Bin
Journal:  Front Cell Neurosci       Date:  2022-06-22       Impact factor: 6.147

Review 2.  Ketamine-New Possibilities in the Treatment of Depression: A Narrative Review.

Authors:  Mateusz Kowalczyk; Edward Kowalczyk; Paweł Kwiatkowski; Łukasz Łopusiewicz; Monika Sienkiewicz; Monika Talarowska
Journal:  Life (Basel)       Date:  2021-11-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.